filmov
tv
PARP inhibitors – a cancer drug discovery story | Professor Ruth Plummer FMedSci
Показать описание
How does a new cancer drug go from laboratory discovery to hospital treatment? Professor Ruth Plummer FMedSci shares her story taking an ovarian cancer treatment from an academic drug discovery project to a treatment now licensed in the USA and Europe.
Professor Plummer is part of the team that discovered the ovarian cancer drug rucaparib (Rubraca®). Rucaparib inhibits the enzyme poly ADP ribose polymerase (PARP), and offers hope to the hundreds of women who are diagnosed each year with inoperable tumours.
Professor Plummer is Professor of Experimental Cancer Medicine at Newcastle University.
Professor Plummer gave this presentation ‘Rucaparib – a story of academic cancer drug discovery and development’ as part of the Academy of Medical Sciences New Fellow's Admissions Day 2018, held on 27 June. On this day, the Academy welcomed newly elected Fellows for their formal admission.
Read more about Professor Plummer's work
For more information about New Fellows Day 2018, visit
Find the Academy of Medical Sciences online:
Professor Plummer is part of the team that discovered the ovarian cancer drug rucaparib (Rubraca®). Rucaparib inhibits the enzyme poly ADP ribose polymerase (PARP), and offers hope to the hundreds of women who are diagnosed each year with inoperable tumours.
Professor Plummer is Professor of Experimental Cancer Medicine at Newcastle University.
Professor Plummer gave this presentation ‘Rucaparib – a story of academic cancer drug discovery and development’ as part of the Academy of Medical Sciences New Fellow's Admissions Day 2018, held on 27 June. On this day, the Academy welcomed newly elected Fellows for their formal admission.
Read more about Professor Plummer's work
For more information about New Fellows Day 2018, visit
Find the Academy of Medical Sciences online:
0:02:47
What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science Illustrated
0:01:43
PARP Inhibitors for Prostate Cancer
0:03:05
An Overview of PARP Inhibitors in Ovarian Cancer
0:01:26
PARP Inhibitors for Maintenance Therapy in Ovarian Cancer
0:59:14
PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023
0:03:12
PARP-inhibitors: A New Generation of Cancer Drugs
0:03:45
PARP inhibitors for ovarian cancer
0:01:22
Overcoming resistance to PARP inhibition in ovarian cancer
0:02:38
Seminar Clips: PARP Inhibitors and BRRCA1/2 Cancers- Susan Domchek, MD | Stanford Cancer Institute
0:01:01
Choosing the correct PARP inhibitor for prostate cancer
0:06:22
Do I Need PARP Inhibitors To Treat My Breast Cancer? What to Expect, Eligibility, and Side Effects
0:04:12
PARP Inhibitors
0:01:27
PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian Cancer
0:11:49
BRCA & PARP Inhibitors: Targeted Chemotherapy | #MarkScholzMD #AlexScholz @PCRI
0:03:58
BRCA+ Breast Cancer: The Advent of PARP Inhibitors
0:01:38
Updates in PARP inhibition for ovarian cancer
0:01:27
Dr. Litton on the Impact of PARP Inhibitors in Breast Cancer
0:03:31
Distinguishing Between PARP Inhibitors in Breast Cancer
0:03:06
Recurrent Ovarian Cancer: Choosing a PARP Inhibitor
0:02:38
Assessing the role of PARP inhibitors and immunotherapy in ovarian cancer
0:07:09
Ovarian Cancer: Comparisons Between PARP Inhibitors
0:05:53
Adverse-Effect Profiles of PARP Inhibitors in Ovarian Cancer
1:27:23
The Role of PARP Inhibitors in Advanced Prostate Cancer (2023)
0:00:31
Which mutations benefit most from PARP inhibitors in prostate cancer?
Комментарии